Neutrophil hypersegmentation in children receiving angiotensin converting enzyme inhibitors

Vedat Okutan1, A Emin Kürekçi, S Umit Sarici

  • 1Department of Pediatrics, Gülhane Military Medical Academy, Ankara, Turkey.

Insights

Angiotensin converting enzyme inhibitors, like captopril and enalapril, were linked to neutrophil hypersegmentation in children with heart disease. This previously unreported finding suggests a potential impact on the hematopoietic system from these common cardiac medications.

Area of Science:

  • Pediatric Cardiology
  • Hematology
  • Pharmacology

Background:

  • Angiotensin converting enzyme (ACE) inhibitors are widely used for pediatric cardiac conditions.
  • The bone marrow's renin-angiotensin system may influence hematopoietic processes.
  • A potential link between ACE inhibition and hematopoietic changes, specifically granulocyte morphology, was hypothesized.

Purpose of the Study:

  • To prospectively investigate the effect of ACE inhibitors on neutrophil morphology, particularly segmentation, in children.
  • To compare neutrophil morphology in children with cardiac disease on ACE inhibitors versus healthy controls.

Main Methods:

  • A prospective study involving 40 children (2-16 years) on ACE inhibitors (captopril or enalapril) and 40 age/sex-matched healthy controls.
  • Comprehensive blood tests including complete blood count and peripheral blood smear analysis.
  • Blinded evaluation of peripheral blood smears by pediatric hematologists to assess neutrophil segmentation.

Main Results:

  • Significantly higher incidence of neutrophil hypersegmentation in the ACE inhibitor group compared to controls.
  • Mean neutrophil lobe count was significantly elevated in children receiving ACE inhibitors.
  • Neutrophil hypersegmentation associated with ACE inhibitor use in children is a novel finding.

Conclusions:

  • ACE inhibitor use in children with cardiac disease is associated with neutrophil hypersegmentation.
  • The underlying pathophysiological mechanisms require further investigation.
  • This finding highlights a potential, previously unrecognized effect of ACE inhibitors on the hematopoietic system.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Acute Pyelonephritis I: Introduction01:27

Acute Pyelonephritis I: Introduction

Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...